Pharmaceutical News

RSS

Dolutegravir drug offers added benefit in HIV patients

Dolutegravir has been approved since January 2014 in combination with other antiretroviral drugs for the treatment of human immunodeficiency virus (HIV) infected adults and adolescents above 12 years of age.

22 May 2014

School-based influenza vaccine programs limited by low rates of reimbursement

School-based influenza vaccine programs have the potential to reach many children at affordable costs and with parental support, but these programs are limited by low rates of reimbursement from third-party payers, according to recently published study results by researchers from the University of Colorado School of Medicine.

21 May 2014

Combination of metformin and rapamycin shows potential in treating aging and related diseases

A proven approach to slow the aging process is dietary restriction, but new research in the Linus Pauling Institute at Oregon State University helps explain the action of a drug that appears to mimic that process - rapamycin.

21 May 2014

Serious complications due to anesthesia during childbirth are very rare

Expectant mothers concerned about receiving an epidural, spinal or general anesthesia during childbirth can breathe a little easier. According to a study published in the June issue of Anesthesiology, the official medical journal of the American Society of Anesthesiologists, serious complications due to anesthesia during childbirth are very rare, occurring in one out of every 3,000 deliveries.

21 May 2014

NIDA guides target both teens and parents with up-to-date science-based facts on marijuana

Two updated booklets about marijuana for teens and their parents will help families sort out marijuana myths from science-based facts. The revamped tools come from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health.

21 May 2014

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

Edison Pharmaceuticals has announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has granted Orphan Designation to EPI-743 for the treatment of Leigh syndrome.

21 May 2014

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., has announced that the United States (U.S.) Food and Drug Administration (FDA) simultaneously approved a new biologic therapy, Entyvio™ (vedolizumab), for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).

21 May 2014

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Quoting Mike Snowden (VP & Head of Discovery Sciences, AstraZeneca), “it’s where biology meets chemistry”. It’s where for the first time a target protein can be probed for novel molecules that modulate its function, of course we want to do this to prove a hypothesis that these proteins are drug targets with the potential to deliver innovative medicines.

20 May 2014

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Aradigm Corporation (the "Company") today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead inhaled antibiotic candidate, Pulmaquin®, as a Qualified Infectious Disease Product (QIDP).

20 May 2014

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Cardiome Pharma Corp. today announced an agreement with AOP Orphan Pharmaceuticals AG, headquartered in Vienna, Austria, to commercialize AGGRASTAT® (tirofiban HCl) in selected European markets.

20 May 2014

Existing pharmaceutical drugs may offer effective therapies against MERS

A series of research articles published ahead of print in the journal Antimicrobial Agents and Chemotherapy have identified a number of existing pharmaceutical drugs and compounds under development that may offer effective therapies against Middle East Respiratory Syndrome (MERS).

20 May 2014

Novel drug for patients with inoperable CTEPH shows improvement in international trial

After a year of being treated with a novel drug, patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and those with persistent or recurrent pulmonary hypertension after an operation for the disease showed sustained improvement in a multicenter, international trial presented at the 2014 American Thoracic Society International Conference.

20 May 2014

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US.

20 May 2014

New technique can predict which stroke victims will benefit from clot-busting drugs

Johns Hopkins researchers say they have developed a technique that can predict — with 95 percent accuracy — which stroke victims will benefit from intravenous, clot-busting drugs and which will suffer dangerous and potentially lethal bleeding in the brain.

20 May 2014

TSRI chemists develop correct structure of highly promising anticancer compound

Chemists at The Scripps Research Institute (TSRI) have determined the correct structure of a highly promising anticancer compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials in cancer patients.

20 May 2014

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Two studies of the anti-depressive drug duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), compared its effectiveness and safety to either fluoxetine or placebo in children and adolescents with major depressive disorder (MDD).

20 May 2014

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Taking olive oil supplements may counteract some of the adverse cardiovascular effects of exposure to air pollution, according to a new study presented at the 2014 American Thoracic Society International Conference.

19 May 2014

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Endo International plc announced today that affiliates of the company have completed the acquisition of worldwide rights to Sumavel® DosePro® (sumatriptan injection), a needle-free delivery system for subcutaneous use, from Zogenix, Inc, for $85 million in cash and rights to additional cash payments based on the achievement of certain commercial milestones.

19 May 2014

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

A new subcutaneous formulation of RoActemra® (tocilizumab) has today been launched providing thousands of UK rheumatoid arthritis (RA) patients with a potentially life-changing treatment option.1

19 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

Pharmaceutical News

Dolutegravir drug offers added benefit in HIV patients

School-based influenza vaccine programs limited by low rates of reimbursement

Combination of metformin and rapamycin shows potential in treating aging and related diseases

Serious complications due to anesthesia during childbirth are very rare

NIDA guides target both teens and parents with up-to-date science-based facts on marijuana

Edison Pharmaceuticals' EPI-743 granted orphan designation for Leigh syndrome in Japan

FDA approves Takeda's Entyvio for severe active ulcerative colitis and Crohn's disease

The future of high throughput screening: an interview with Mark Wigglesworth, Director High Throughput Screening, AstraZeneca

Aradigm receives QIDP designation for its inhaled antibiotic candidate, Pulmaquin

Cardiome, AOP Orphan team up to commercialize AGGRASTAT in select European markets

Existing pharmaceutical drugs may offer effective therapies against MERS

Novel drug for patients with inoperable CTEPH shows improvement in international trial

Orexo US partners with inVentiv Health to market Zubsolv sublingual tablets in the US

New technique can predict which stroke victims will benefit from clot-busting drugs

TSRI chemists develop correct structure of highly promising anticancer compound

Study compares effectiveness of duloxetine and fluoxetine in children with MDD

Olive oil supplements may counteract adverse cardiovascular effects of air pollution

Endo acquires worldwide rights to Zogenix' sumatriptan injection

Convenient new treatment option for rheumatoid arthritis sufferers offers patient freedom and control of disease

Study shows commonly used statin drug does not reduce acute COPD exacerbations

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News